A pharmacokinetic bridging study of NKPL66 (CaPre)
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2017
At a glance
- Drugs NKPL 66 (Primary)
- Indications Hypertriglyceridaemia
- Focus Pharmacokinetics
- Sponsors Acasti Pharma
- 07 Jun 2017 According to an Acasti Pharma media release, results from this study were presented at the National Lipid Association Scientific Sessions.
- 12 Apr 2017 Results will be presented at the National Lipid Association Scientific Sessions 2017, according to an Acasti Pharma media release.
- 12 Jan 2017 According to an Acasti Pharma media release, the full report of this study has been submitted to the FDA. Company plans to discuss the results of this study and gain guidance on planned Phase 3 clinical study protocol in patients with severe hypertriglyceridemia (see profile 272010) with the FDA in a meeting scheduled in the first quarter of 2017.